EUCTR2016-003553-15-HUActive, not recruitingPhase 1
A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta Active-Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
Generon (Shanghai) Corporation Ltd.0 sites400 target enrollmentStarted: January 30, 2018Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 400
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- Female
Inclusion Criteria
- •1) Show evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.
- •2) Females =18 years of age and <75 years of age.
- •3) Diagnosed with Stage I-III breast cancer.
- •4) Subject is scheduled to undergo 4 cycles of neoadjuvant or adjuvant TC chemotherapy (docetaxel, cyclophosphamide, 75, 600 mg/m2, respectively).
- •5) ECOG Performance status of =2.
- •6) WBC count =4.0 × 109/L, hemoglobin =11.5 g/dL and a platelet count =150 × 109/L.
- •7) Demonstrate adequate renal, hepatic, and cardiac function (liver function tests [alanine aminotransferase {ALT}, aspartate aminotransferase {AST}, alkaline phosphatase, and total bilirubin]) should be less than 2.5x the upper limits of normal (ULN). Serum creatinine should be less than 1.7x ULN.
- •8) All subjects must agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 320
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
Exclusion Criteria
- •1) Subject is <18 or =75 years of age.
- •2) Disease progression has occurred while receiving a taxane regimen.
- •3) Subject has undergone radiation therapy within 4 weeks of enrollment.
- •4) Subject has undergone bone marrow or stem-cell transplantation.
- •5) Subject has a history of prior malignancy other than breast cancer that is NOT in remission.
- •6) Subjects that have used G-CSF or any other drug that may potentiate the release of neutrophils (i.e., lithium) within 6 weeks of the screening period are excluded.
- •7) Subject has had chemotherapy within 180 days of screening.
- •8) Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, electrocardiogram (ECG) test, or any other relevant test.
- •9) History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.
- •10) Unwillingness to participate in the study.
- •11) Any underlying medical condition that, in the Investigator’s opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events.
- •12) Receiving other investigational drugs or biologics within 1 month or five half lives of enrollment (if known), which ever is less.
- •13) Any condition, which can cause splenomegaly.
- •14) Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.
- •15) ALT, AST, alkaline phosphatase, total bilirubin =2.5x ULN.
- •16) Subject with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of Hepatitis C.
- •17) Women who are pregnant or breast-feeding.
- •18) Subject known to be seropositive for HIV, or who have had an AIDS defining illness or a known immunodeficiency disorder.
- •19) Subject with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated.
- •20) Subjects with Sickle Cell disease
- •21) Subjects with known hypersensitivity to E.coli derived proteins‚ pegfilgrastim‚ filgrastim, or any other component of the study drug.
Investigators
Similar Trials
Active, not recruiting
Phase 1
F-627 is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer therapy associated with a clinically significant incidence of febrile neutropeniaEUCTR2016-003553-15-BGGeneron (Shanghai) Corporation Ltd.400
Active, not recruiting
Phase 1
F-627 is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer therapy associated with a clinically significant incidence of febrile neutropeniaWomen, between 18 and 75 years of age that have been diagnosed with Stage I-III breast cancer and are scheduled to undergo chemotherapy. This is a prophylaxis for myleotoxic chemotherapy induced neutropenia.MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016288Term: Febrile neutropeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-003553-15-LVGeneron (Shanghai) Corporation Ltd.400
Active, not recruiting
Phase 1
A Research Study to Gather Scientific Information About the Efficacy, Safety, and Tolerability of the Investigational Drug APL-2 In Treating Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH), a Disease Associated With Anemia, In A Randomly Assigned Comparison With the Current Standard of Care Treatment Approved for PNH At Multiple Research Centres.PNH is an acquired, rare, clonal, non-malignant hematologic disease characterized by complement-mediated RBC hemolysis with or without hemoglobinuria, an increased susceptibility to thrombotic episodes, and/or some degree of bone marrow dysfunction.PNH is caused by complement-mediated lysis of erythrocyte clones lacking functional CD55 and CD59 on their surface. These RBCs are particularly susceptible to the MAC and have been shown to lyse readily in the presence of complement activation.MedDRA version: 20.1Level: LLTClassification code 10055629Term: Paroxysmal nocturnal hemoglobinuriaSystem Organ Class: 100000004857EUCTR2017-004268-36-ESApellis Pharmaceuticals, Inc.80
Active, not recruiting
Phase 1
A Research Study to Gather Scientific Information About the Efficacy, Safety, and Tolerability of the Investigational Drug APL-2 In Treating Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH), a Disease Associated With Anemia, In A Randomly Assigned Comparison With the Current Standard of Care Treatment Approved for PNH At Multiple Research Centres.PNH is an acquired, rare, clonal, non-malignant hematologic disease characterized by complement-mediated RBC hemolysis with or without hemoglobinuria, an increased susceptibility to thrombotic episodes, and/or some degree of bone marrow dysfunction.PNH is caused by complement-mediated lysis of erythrocyte clones lacking functional CD55 and CD59 on their surface. These RBCs are particularly susceptible to the MAC and have been shown to lyse readily in the presence of complement activation.MedDRA version: 20.1Level: LLTClassification code 10055629Term: Paroxysmal nocturnal hemoglobinuriaSystem Organ Class: 100000004857EUCTR2017-004268-36-NLApellis Pharmaceuticals, Inc.80
Active, not recruiting
Phase 1
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy alone for Patients With Lung Cancer (POSEIDON).First-line patients with metastatistic non-small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusionsMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2017-000920-81-PLAstraZeneca AB1,000